Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin

Journal of Viral Hepatitis

Volumn 25, Issue 4, 2018, Pages 354-362

  Younossi, Z M ^a,b   Stepanova, M ^c   Schwarz, K B ^d   Wirth, S ^e   Rosenthal, P ^f   Gonzalez Peralta, R ^g   Murray, K ^h   Henry, L ^c   Hunt, S ^c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c Center for Outcomes Research in Liver Diseases   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e Children's Hospital   (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

direct acting antiviral; emotional well being; paediatric; physical well being; social functioning

Indexed keywords

RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADOLESCENT; AFRICAN AMERICAN; AGGRESSION; ANXIETY; ARTICLE; ASTHENIA; ASTHMA; ATTENTION DEFICIT DISORDER; CAUCASIAN; CHILD; COGNITION; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GENOTYPE; HEALTH STATUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; LIVER CELL CARCINOMA; MALE; MENTAL DISEASE; MOOD DISORDER; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PANIC; PHASE 2 CLINICAL TRIAL; POST HOC ANALYSIS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SELF REPORT; SLEEP DISORDER; SOCIAL PROBLEM; SOCIAL STATUS; TREATMENT DURATION; VERTICAL TRANSMISSION; CHRONIC HEPATITIS C; CLINICAL TRIAL; COMBINATION DRUG THERAPY; PSYCHOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; QUALITY OF LIFE; RIBAVIRIN; SOFOSBUVIR; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 85039156031     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12830     Document Type: Article

References (37)

1. El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol. 2013;19:7880-7888.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.
3. Jhaveri R, Grant W, Kauf TL, McHutchison J. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. J Pediatr. 2006;148:353-358.
4. Centers for Disease Control. Hepatitis C virus infection among adolescents and young adults — Massachusetts, 2002-2009. Morb Mortal Wkly Rep. 2011;60:537-541.
5. El-Karaksy H, Anwar GH, El-Raziky MS, et al. Anti-HCV prevalence among diabetic and nondiabetic Egyptian children. Curr Diabetes Rev. 2010;6:388-392.
6. Barakat SH, El-Bashir N. Hepatitis C virus infection among healthy Egyptian children: prevalence and risk factors. J Viral Hepat. 2011;18:779-784.
7. Khaderi S, Shepherd R, Goss JA, Leung DH. Hepatitis C in the pediatric population: transmission, natural history, treatment and liver transplantation. World J Gastroenterol. 2014;20:11281-6.
8. Rerksuppaphol S, Hardikar W, Dore GJ. Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. J Gastroenterol Hepatol. 2004;19:1357-62.
9. European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis. 2005;41:45-51.
10. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355:887-891.
11. World Health Organization (WHO). Schistosomiasis. February 2016. http://www.who.int/mediacentre/factsheets/fs115/en/ Accessed September 17, 2017.
12. El-Kamary SS, Hashem M, Saleh DA, Abdelwahab SF, Sobhy M, Shebl FM, et al. Hepatitis C virus-specific cell-mediated immune responses in children born to mothers infected with hepatitis C virus. J Pediatr. 2013;162:148-154.
13. Rodrigue JR, Balistreri W, Haber B, et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr. 2009 Mar;48:341-7.
14. ™ 4.0. Electron Physician. 2015;7:1214-9.
15. Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12 to 17 years old with hepatitis c virus genotype 1 infection. Hepatology. 2017;66:371-378.
16. Wirth S, Rosenthal P, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2017;66:1102-1110.
17. Younossi ZM, Stepanova M, Balistreri W, et al. Health-related quality of life in adolescent patients with hepatitis C genotype 1 treated with sofosbuvir and ledipasvir. J Pediatr Gastroenterol Nutr. 2017. doi:10.1097/MPG.0000000000001754. [Epub ahead of print]
18. Varni J. W., Burwinkle T. M., Seid M. The PedsQL 4.0 as a school population health measure: feasibility, reliability, and validity. Qual Life Res. 2006;15:203-215.
19. Maskell J, Newcombe P, Martin G, Kimble R. Psychosocial functioning differences in pediatric burn survivors compared with healthy norms. J Burn Care Res. 2013;34:465-76.
20. ® pediatric global health measure. Qual Life Res. 2016 Mar;25:739-51.
21. Goldfield GS, Cameron JD, Murray M, et al. Screen time is independently associated with health-related quality of life in overweight and obese adolescents. Acta Paediatr. 2015;104:e448-54.
22. Nydegger A, Srivastava A, Wake M, Smith AL, Hardikar W. Health-related quality of life in children with hepatitis C acquired in the first year of life. J Gastroenterol Hepatol. 2008;23:226-30.
23. Rodrigue JR, Balistreri W, Haber B, et al. Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children. Hepatology. 2011;53:1468-75.
24. Iorio R, Pensati P, Botta S, et al. Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infec Dis J. 1997;16:984-990.
25. Younossi I, Weinstein A, Stepanova M, Hunt S, Younossi ZM. Mental and Emotional Impairment in Patients With Hepatitis C is Related to Lower Work Productivity. Psychosomatics. 2016;57:82-8.
26. Younossi ZM, Stepanova M, Nader F, Lam B, Hunt S. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life. Aliment Pharmacol Ther. 2015;42:286-95.
27. Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015;63:337-45.
28. Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C–the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41:497-520.
29. Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015;63:337-45.
30. Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology. 2015;61:1798-808.
31. Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis. 2014;15(46 Suppl 5):S186-96.
32. Younossi ZM, Stepanova M, Henry L, Nader F, Hunt S. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis c treated with different anti-viral regimens. Am J of Gastroenter. 2016;111:808-816.
33. Logan DE, Simons LE. Development of a group intervention to improve school functioning in adolescents with chronic pain and depressive symptoms: a study of feasibility and preliminary efficacy. J Pediatr Psychol. 2010;35:823-836.
34. Suris JC, Michaud PA, Viner R. The adolescent with a chronic condition. Part I: developmental issues. Arch Dis Child. 2004;89:938-942.
35. Compas BE, Jaser SS, Dunn MJ, Rodriguez EM. Coping with Chronic Illness in Childhood and Adolescence. Annu Rev Clin Psychol. 2012;27:455-480.
36. Gutierrez-Colina AM, Eaton CK, Lee JL, LaMotte J, Blount RL. Health-related quality of life and psychosocial functioning in children with tourette syndrome: parent-child agreement and comparison to healthy norms. J Child Neurol. 2015;30:326-332.
37. Pickard AS, Knight SJ. Proxy evaluation of health-related quality of life: a conceptual framework for understanding multiple proxy perspectives. Med Care. 2005;43:493-499.